Role of EGFR transactivation in angiotensin II signaling to extracellular regulated kinase in preglomerular smooth muscle cells

Hypertension

Volumn 41, Issue 3 II, 2003, Pages 781-786

  Andresen, Bradley T ^a,b,c   Linnoila, Jenny J ^a   Jackson, Edwin K ^a,b   Romero, Guillermo G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Angiotensin II; Epidermal growth factors; Extracellular regulated kinase; Phosphoinositide 3 kinase; Phospholipase D; Transactivation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOTENSIN; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D; RAF PROTEIN; RHO FACTOR; WORTMANNIN;

ANIMAL CELL; CELL MEMBRANE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLOMERULUS; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSACTIVATION;

ANDROSTADIENES; ANGIOTENSIN II; ANIMALS; ENZYME INHIBITORS; KIDNEY GLOMERULUS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH; PHOSPHOLIPASE D; PHOSPHORYLATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0037340055     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000049426.61176.DF     Document Type: Conference Paper

References (24)

1. Mutalin MM, Karzoun NA, Gaber L, Khandekar Z, Benter IF, Saeed AE, Parmentier JH, Estes A, Malik KU. Angiotensin II-induced hypertension: contribution of ras GTPase/mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension. 2000;36:604-609.
2. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein- coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884-888.
3. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998;273:8890-8896.
4. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells: metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 2001;276:7957-7962.
5. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:489-495.
6. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA . 1999;96:1415-1420.
7. Shome K, Rizzo MA, Vasudevan C, Andresen B, Romero G. The activation of phospholipase D by endothelin-1, angiotensin II, and platelet derived growth factor in vascular smooth muscle A10 cells is mediated by small G proteins of the ADP-ribosylation factor family. Endocrinology. 2000;141:2200-2208.
8. Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-o-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J Biol Chem. 1996;271:8472-8480.
9. Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA, Watkins SC, Romero G. Phospholipase D and its product, phosphatidic acid, mediate agonist- dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem. 1999;274:1131-1139.
10. Rizzo MA, Shome K, Watkins SC, Romero G. The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem. 2000;275:23911-23918.
11. Grisk O, Kloting I, Exner J, Spiess S, Schmidt R, Junghans D, Lorenz G, Rettig R. Long-term arterial pressure in spontaneously hypertensive rats is set by the kidney. J Hypertens. 2002;20:131-138.
12. Madeddu P, Anania V, Varoni MV, Parpaglia PP, Demontis MP, Fattaccio MC, Palomba D, Pollock D, Glorioso N. Prevention by blockade of angiotensin subtype 1-receptors of the development of genetic hypertension but not its heritability. Br J Pharmacol. 1995;115:557-562.
13. Ferrone RA, Antonaccio MJ. Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225). Eur J Pharmacol. 1979;60:131-137.
14. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, Carelli C, Galen FX, Menard J, Corvol P. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation. 1990;81:1899-1910.
15. Freeman EJ, Ferrario CM, Tallant EA. Angiotensins differentially activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats. Am J Hypertens. 1995;8:1105-1111.
16. Andresen BT, Jackson EK, Romero GG. Angiotensin II signaling to phospholipase D in renal microvascular smooth muscle cells in spontaneously hypertensive rats. Hypertension. 2001;37:635-639.
17. Kubo T, Ibusuki T, Saito E, Kambe T, Hagiwara Y. Vascular mitogen-activated protein kinase activity is enhanced via angiotensin system in spontaneously hypertensive rats. Eur J Pharmacol. 1999;372:279-285.
18. Touyz RM, El Mabrouk M, He G, Wu XH, Schiffrin EL. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res. 1999;84:505-515.
19. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994;265:1093-1095.
20. Yart A, Laffargue M, Mayeux P, Chretien S, Peres C, Tonks N, Roche S, Payrastre B, Chap H, Raynal P. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem. 2001;276:8856-8864.
21. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001;70:535-602.
22. Virbasius JV, Guilherme A, Czech MP. Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J Biol Chem. 1996;271:13304-13307.
23. Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC, Waterfield MD. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J. 1997;326(pt 1):139-147.
24. Yart A, Roche S, Wetzker R, Laffargue M, Tonks N, Mayeux P, Chap H, Raynal P. A function for phosphoinositide 3-kinase β-lipid products in coupling βγ to Ras activation in response to lysophosphatidic acid. J Biol Chem. 2002;277:21167-21178.